Abstracts Archive - Page 823 of 2607 - ACR Meeting Abstracts

Abstract Number: 1768 • ACR Convergence 2021
Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity
Risa Wakiya¹, Kiyo Ueeda¹, Hiromi Shimada¹, Shusaku Nakashima¹, Mikiya Kato¹, Taichi Miyagi², Mansour mai¹, Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: In systemic lupus erythematosus (SLE), atherosclerosis is strongly associated with vital prognosis. On the other hand, arteriosclerosis is strongly influenced by serum adipokines. The…
Abstract Number: 1769 • ACR Convergence 2021
BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects
Manoj Chiney¹, Ihab Girgis², Melanie Harrison¹, Xiaoping Zhang¹, Yun Shen³, Michelle Dawes¹, Lixian Dong², Diane Shevell³, Urvi Aras¹ and Bindu Murthy³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville
Background/Purpose: Toll like receptor (TLR) 7 and TLR8 are activated as part of the disease pathophysiology of systemic lupus erythematosus (SLE), including lupus nephritis (LN),…
Abstract Number: 1770 • ACR Convergence 2021
Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic
Gary Gilkeson¹, Diane Kamen¹, S Sam Lim², Rosalind Ramsey-Goldman³, Kenneth Kalunian⁴, Saira Sheikh⁵, Mariko Ishimori⁶ and Daniel Wallace⁷, ¹Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Northwestern University, Chicago, IL, ⁴UC San Diego, La Jolla, CA, ⁵University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Attune Health, Beverly Hills, CA
Background/Purpose: There is heightened interest in the use of mesenchymal stromal cells (MSCs) for the treatment of autoimmune diseases. There are a number of reports…
Abstract Number: 1771 • ACR Convergence 2021
First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8
Melanie Harrison¹, Manoj Chiney¹, Diane Shevell², Lixian Dong³, Michelle Dawes¹ and Ihab Girgis³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Lawrenceville, ³Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Toll-like receptor (TLR)7 and TLR8 are endosomal receptors that are normally activated by pathogen-associated RNA. They are also activated by self-RNA as part of…
Abstract Number: 1772 • ACR Convergence 2021
Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial
Antoine Enfrein¹, Beatrice Clemenceau², Soraya Saiagh³, Céline Bressollette⁴, Zahir Amoura⁵, Henri Vie² and Mohamed Hamidou¹, ¹Médecine interne, CHU de Nantes, Nantes, France, ²Inserm U1232, Université de Nantes, Nantes, France, ³Unité de Thérapie Cellulaire et Génique, CHU de Nantes, Nantes, France, ⁴Laboratoire de Virologie, CHU de Nantes, Nantes, France, ⁵Médecine interne, Hôpital Pitié Salpêtrière, AP-HP, Paris, France
Background/Purpose: Epstein-Barr Virus (EBV) has been suggested as a potential environmental factor in systemic lupus erythematosus (SLE) onset and disease activity. Here, we report the…
Abstract Number: 1773 • ACR Convergence 2021
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
Joris Diels¹, Pushpike Thilakarathne², Agata Schubert³, Fareen Hassan⁴, Steven Peterson⁵ and Wim Noël¹, ¹Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ²JanssenCilag Ltd, HEMAR Department, Beerse, Belgium, ³Janssen-Cilag Poland, HEMAR Department, Warsaw, Poland, ⁴Janssen-Cilag Ltd, HEMAR Department, High Wycombe, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ
Background/Purpose: Guselkumab is an anti-interleukin (IL)-23 monoclonal antibody recently approved for the treatment of psoriatic arthritis (PsA). In two large Phase III trials of patients…
Abstract Number: 1774 • ACR Convergence 2021
Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
Michelle Mulder¹, Xuehui He², Juul van den Reek², Paulo Urbano², Charlotte Kaffa², Xinhui Wang³, Bram van Cranenbroek², Esther van Rijssen², Frank van den Hoogen⁴, Irma Joosten², Wynand Alkema⁵, Elke de Jong², Ruben Smeets², Mark Wenink⁶ and Hans Koenen², ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboud University Medical Center, Nijmegen, Netherlands, ³University of Luxembourg, Belvaux, Luxembourg, ⁴Sint Maartenskliniek, Ubbergen, Netherlands, ⁵Hanze University of Applied Sciences, Groningen, Netherlands, ⁶Sint Maartenskliniek, Malden, Netherlands
Background/Purpose: Early detection of psoriatic arthritis (PsA) in psoriasis (Pso) patients is crucial for timely treatment and prevention of structural joint damage. We aimed to…
Abstract Number: 1775 • ACR Convergence 2021
Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis
Timothy Kwok¹, Mitchell Sutton², Richard Cook³, Daniel Pereira⁴ and Dafna Gladman⁵, ¹Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Isolated axial involvement exists in 2 to 5% of all psoriatic arthritis (PsA) patients. However, it is currently unknown whether patients with isolated axial…
Abstract Number: 1776 • ACR Convergence 2021
Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial
Pamela Weiss¹, Cora Sears¹, Timothy Brandon¹, Rui Xiao², Tory Aquino³, Kweli Archie¹, Aamena Hameed⁴, English Holland⁵, Miles Holland⁵, Asad Khan¹, Melanie Kohlheim⁶, Jennifer Leal⁷, Lynn Murphy⁸, Sean Murphy⁸, Antoinette Neu⁹, Emily Neu⁹, Jerome Neu⁹, Justin Neu⁹, Rachel Richmond¹⁰, Theresa Suplee¹¹, Dylan Suplee¹¹ and Christopher Forrest¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³Children's Hospital of Philadelphia, Aliquippa, PA, ⁴Children's Hospital of Philadelphia, Franklin Park, NJ, ⁵Children's Hospital of Philadelphia, Williamsburg, VA, ⁶Children's Hospital of Philadelphia, Granville, OH, ⁷Children's Hospital of Philadelphia, Columbus, OH, ⁸Children's Hospital of Philadelphia, Haddon Heights, NJ, ⁹Children's Hospital of Philadelphia, Sidney, OH, ¹⁰Children's Hospital of Philadelphia, Albuquerque, NM, ¹¹Children's Hospital of Philadelphia, Maple Shade, NJ
Background/Purpose: The BACK-OFF JSpA Study is a randomized pragmatic trial that will investigate different TNFi de-escalation strategies for children who have sustained asymptomatic disease. As…
Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Alexis Ogdie-Beatty¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵, Steven Hass⁶ and Kaleb Michaud⁷, ¹University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, CA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵Novartis Pharmaceuticals Corporation, Weehawken, NJ, ⁶H.E. Outcomes, LLC, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…
Abstract Number: 1778 • ACR Convergence 2021
The Role of Cathepsin G in Joint Destruction in Patients with Psoriatic Arthritis
Mariela Geneva-Popova¹, Stanislava Popova¹ and Anastas Batalov², ¹Medical University, Faculty of Medicine, Department of Propedeutic of Internal Diseases, Plovdiv, Bulgaria, ²UMHAT KASPELA, Plovdiv, Bulgaria
Background/Purpose: Cathepsin G (CTSG) is a member of the serine protease family. It is stored in primary granules of myeloid cells, dendritic cells, plasma cells,…
Abstract Number: 1779 • ACR Convergence 2021
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Nancy Shadick¹, Kumiko Schnock², Vivi Feather², Jing Cui³, Gabriela Maica², Alexa Marshall², Wynona Francis², Muibat Yussuff², Lourdes Maria Perez Chada², Michael E. Weinblatt² and Joseph Merola⁴, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
Abstract Number: 1780 • ACR Convergence 2021
Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis
Sabahath Jaleel¹, Yael Ross¹ and Marina Magrey², ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve Universtiy at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Racial heterogeneity of the US population makes it imperative to study the racial differences in clinical characteristics, medication use and co-morbidities of PsA patients…
Abstract Number: 1781 • ACR Convergence 2021
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
Megan Meier¹, Jessica Walsh² and Shaobo Pei³, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA) and contribute to unnecessary impairments in quality of life and function. Screening surveys for identifying at-risk…
Abstract Number: 1782 • ACR Convergence 2021
Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies
Robert Chao¹, George Reed², Joel Kremer³ and Arthur Kavanaugh⁴, ¹Inova Health System, Fairfax, VA, ²University of Massachusetts, Worcester, MA, ³Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Evidence on the treatment of enthesitis, a common feature of psoriatic arthritis (PsA), is limited. This post-hoc, cross-sectional study examined if prevalent treatment choices…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].